肾炎康复片联合双倍剂量厄贝沙坦治疗慢性肾脏疾病的随机对照研究

Random control study on treating CKD with Shenyan Kangfu tablet and double-dose irbesartan

目的:评价肾炎康复片联合厄贝沙坦治疗慢性肾脏疾病的有效性。方法:将80例CKD患者随机分为两组,肾炎康复片联合厄贝沙坦组(治疗组)40例,厄贝沙坦组(对照组)40例,疗程为12周,两组均观察治疗前后24h尿蛋白定量,肾功(血肌酐、血尿素氮、血尿酸及eGFR),血浆白蛋白,C反应蛋白及中医症候积分。结果:两组治疗后24h尿蛋白定量、肾功、ALB、中医症候积分(面色无华、少气乏力、腰痛及浮肿)均较治疗前明显改善,差异有统计学意义(P<0.05);治疗组与对照组相比,治疗后24h尿蛋白定量、UA、ALB、CRP及面色无华、少气乏力、手足心热、口干咽燥等中医症候积分改善均优于对照组,差异有统计学意义(P<0.05)。结论:肾炎康复片联合双倍剂量厄贝沙坦能有效延缓CKD进展,改善机体微炎症状态,并有效缓解患者主观症状,提高生存质量。

Objective： To investigate the therapeutic effects of Shenyan Kangfu Tablet （SYKFT） and double-dose irbesartan on chronic kidney disease（CKD）. Methods： 80 CKD patients were randomly divided into two groups, 40 patients in each group. The treatment group was given SYKFT and double-dose irbesartan treatment, while the control group was only given double-dose irbesartan. Both groups were treated for 12 weeks. The urine protein content, kidney function parameters, plasma-albumin content, C reactive protein content and accumulated points of TCM syndromes of both groups 24 hours before and after treatment were observed. Results： The urine protein content, kidney function parameters, ALB and accumulated points of TCM syndromes of both groups 24 hours after treatment significantly improved compared with pretreatment, with significant differences （P〈0.05）. The urine protein content, UA, ALB, CRP and accumulated points of TCM syndromes in the treated group 24 hours after treatment were significantly better than those in the control group （P〈0.05）. Conclusion： SYKFT and double-dose irbesartan can delay the progression of CKD, improve the inflammational state and enhance the prognosis.